2AG4
 
 | | Crystal Structure Analysis of GM2-activator protein complexed with phosphatidylcholine | | Descriptor: | (7R)-4,7-DIHYDROXY-N,N,N-TRIMETHYL-10-OXO-3,5,9-TRIOXA-4-PHOSPHAHEPTACOSAN-1-AMINIUM 4-OXIDE, Ganglioside GM2 activator, ISOPROPYL ALCOHOL, ... | | Authors: | Wright, C.S, Mi, L.Z, Lee, S, Rastinejad, F. | | Deposit date: | 2005-07-26 | | Release date: | 2005-10-25 | | Last modified: | 2023-08-23 | | Method: | X-RAY DIFFRACTION (1.8 Å) | | Cite: | Crystal Structure Analysis of Phosphatidylcholine-GM2-Activator Product Complexes: Evidence for Hydrolase Activity.
Biochemistry, 44, 2005
|
|
2AF9
 | | Crystal Structure analysis of GM2-Activator protein complexed with phosphatidylcholine | | Descriptor: | Ganglioside GM2 activator, ISOPROPYL ALCOHOL, LAURIC ACID, ... | | Authors: | Wright, C.S, Mi, L.Z, Lee, S, Rastinejad, F. | | Deposit date: | 2005-07-25 | | Release date: | 2005-10-25 | | Last modified: | 2023-08-23 | | Method: | X-RAY DIFFRACTION (2 Å) | | Cite: | Crystal Structure Analysis of Phosphatidylcholine-GM2-Activator Product Complexes: Evidence for Hydrolase Activity.
Biochemistry, 44, 2005
|
|
7VVT
 | | SARS-CoV-2 3CL protease (3CLpro) in complex with a covalent inhibitor | | Descriptor: | 3C-like proteinase, N-(3-chlorophenyl)-2-[(2R)-1-ethanoyl-3-oxidanylidene-piperazin-2-yl]ethanamide | | Authors: | Su, H, Nie, T, Li, M, Xu, Y. | | Deposit date: | 2021-11-08 | | Release date: | 2022-03-02 | | Last modified: | 2023-11-29 | | Method: | X-RAY DIFFRACTION (2.51 Å) | | Cite: | In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.
Eur.J.Med.Chem., 231, 2022
|
|
8X7M
 | | CR-bound E46K alpha-synuclein fibrils | | Descriptor: | 4-azanyl-3-[(~{E})-[4-[4-[(~{E})-(1-azanyl-4-sulfo-naphthalen-2-yl)diazenyl]phenyl]phenyl]diazenyl]naphthalene-1-sulfonic acid, Alpha-synuclein | | Authors: | Liu, K.E, Tao, Y.Q, Li, D, Liu, C. | | Deposit date: | 2023-11-24 | | Release date: | 2024-09-11 | | Method: | ELECTRON MICROSCOPY (3 Å) | | Cite: | Binding adaptability of chemical ligands to polymorphic alpha-synuclein amyloid fibrils.
Proc.Natl.Acad.Sci.USA, 121, 2024
|
|
8X7O
 | | PiB-bound E46K mutanted alpha-synuclein fibrils | | Descriptor: | 2-[4-(methylamino)phenyl]-1,3-benzothiazol-6-ol, Alpha-synuclein | | Authors: | Liu, K.E, Tao, Y.Q, Li, D, Liu, C. | | Deposit date: | 2023-11-24 | | Release date: | 2024-09-11 | | Method: | ELECTRON MICROSCOPY (3.5 Å) | | Cite: | Binding adaptability of chemical ligands to polymorphic alpha-synuclein amyloid fibrils.
Proc.Natl.Acad.Sci.USA, 121, 2024
|
|
8X7R
 | | C05-03-bound E46K alpha-synuclein fibrils | | Descriptor: | 2-[(~{E})-4-[6-(methylamino)pyridin-3-yl]but-1-en-3-ynyl]-1,3-benzothiazol-6-ol, Alpha-synuclein | | Authors: | Liu, K.E, Tao, Y.Q, Li, D, Liu, C. | | Deposit date: | 2023-11-24 | | Release date: | 2024-09-11 | | Method: | ELECTRON MICROSCOPY (3 Å) | | Cite: | Binding adaptability of chemical ligands to polymorphic alpha-synuclein amyloid fibrils.
Proc.Natl.Acad.Sci.USA, 121, 2024
|
|
8X7P
 | | CCA-bound E46K alpha-synuclein fibrils | | Descriptor: | Alpha-synuclein, copper;trisodium;18-(2-carboxylatoethyl)-20-(carboxylatomethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18-dihydroporphyrin-21,23-diide-2-carboxylate | | Authors: | Liu, K.E, Tao, Y.Q, Li, D, Liu, C. | | Deposit date: | 2023-11-24 | | Release date: | 2024-09-11 | | Method: | ELECTRON MICROSCOPY (2.7 Å) | | Cite: | Binding adaptability of chemical ligands to polymorphic alpha-synuclein amyloid fibrils.
Proc.Natl.Acad.Sci.USA, 121, 2024
|
|
8X7Q
 | | pFTAA-bound E46K alpha-synuclein fibrils | | Descriptor: | 3''',4'-bis(carboxymethyl)-2,2':5',2'':5'',2''':5''',2''''-quinquethiophene-5,5''''-dicarboxylic acid, Alpha-synuclein | | Authors: | Liu, K.E, Tao, Y.Q, Li, D, Liu, C. | | Deposit date: | 2023-11-24 | | Release date: | 2024-09-11 | | Method: | ELECTRON MICROSCOPY (2.7 Å) | | Cite: | Binding adaptability of chemical ligands to polymorphic alpha-synuclein amyloid fibrils.
Proc.Natl.Acad.Sci.USA, 121, 2024
|
|
8X7L
 | | EB-bound E46K alpha-synuclein fibrils | | Descriptor: | 4-azanyl-6-[[4-[4-[(~{E})-(8-azanyl-1-oxidanyl-5,7-disulfo-naphthalen-2-yl)diazenyl]-3-methyl-phenyl]-2-methyl-phenyl]diazenyl]-5-oxidanyl-naphthalene-1,3-disulfonic acid, Alpha-synuclein | | Authors: | Liu, K.E, Tao, Y.Q, Li, D, Liu, C. | | Deposit date: | 2023-11-24 | | Release date: | 2024-09-11 | | Method: | ELECTRON MICROSCOPY (3.4 Å) | | Cite: | Binding adaptability of chemical ligands to polymorphic alpha-synuclein amyloid fibrils.
Proc.Natl.Acad.Sci.USA, 121, 2024
|
|
8ZLO
 | | F0502B-bound E46K alpha-synuclein fibril | | Descriptor: | 2-bromanyl-4-[(~{E})-2-[6-[2-(2-fluoranylethoxy)ethyl-methyl-amino]-5-methyl-1,3-benzothiazol-2-yl]ethenyl]phenol, Alpha-synuclein | | Authors: | Liu, K.E, Tao, Y.Q, Li, D, Liu, C. | | Deposit date: | 2024-05-20 | | Release date: | 2024-09-11 | | Method: | ELECTRON MICROSCOPY (3.1 Å) | | Cite: | Binding adaptability of chemical ligands to polymorphic alpha-synuclein amyloid fibrils.
Proc.Natl.Acad.Sci.USA, 121, 2024
|
|
8ZLI
 | | BTA-2-bound E46K alpha-synuclein fibrils | | Descriptor: | Alpha-synuclein, ~{N},~{N}-dimethyl-4-(6-methyl-1,3-benzothiazol-2-yl)aniline | | Authors: | Liu, K.E, Tao, Y.Q, Li, D, Liu, C. | | Deposit date: | 2024-05-20 | | Release date: | 2024-09-11 | | Method: | ELECTRON MICROSCOPY (3.4 Å) | | Cite: | Binding adaptability of chemical ligands to polymorphic alpha-synuclein amyloid fibrils.
Proc.Natl.Acad.Sci.USA, 121, 2024
|
|
8ZLP
 | |
8ZMY
 | | F0502B-bound WT polymorph 5a alpha-synuclein fibril | | Descriptor: | 2-bromanyl-4-[(~{E})-2-[6-[2-(2-fluoranylethoxy)ethyl-methyl-amino]-5-methyl-1,3-benzothiazol-2-yl]ethenyl]phenol, Alpha-synuclein | | Authors: | Liu, K.E, Tao, Y.Q, Li, D, Liu, C. | | Deposit date: | 2024-05-24 | | Release date: | 2024-09-11 | | Last modified: | 2024-10-16 | | Method: | ELECTRON MICROSCOPY (2.9 Å) | | Cite: | Binding adaptability of chemical ligands to polymorphic alpha-synuclein amyloid fibrils.
Proc.Natl.Acad.Sci.USA, 121, 2024
|
|
6AKX
 | | The Crystal structure of Human Chemokine Receptor CCR5 in complex with compound 21 | | Descriptor: | C-C chemokine receptor type 5,Rubredoxin,C-C chemokine receptor type 5, N-[(1S)-3-{(3-exo)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl}-1-(thiophen-2-yl)propyl]cyclopentanecarboxamide, NITRATE ION, ... | | Authors: | Zhu, Y, Zhao, Q, Wu, B. | | Deposit date: | 2018-09-04 | | Release date: | 2018-10-24 | | Last modified: | 2024-10-16 | | Method: | X-RAY DIFFRACTION (2.8 Å) | | Cite: | Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
J. Med. Chem., 61, 2018
|
|
5F22
 | | C-terminal domain of SARS-CoV nsp8 complex with nsp7 | | Descriptor: | Non-structural protein, Non-structural protein 7 | | Authors: | Li, S. | | Deposit date: | 2015-12-01 | | Release date: | 2016-01-27 | | Last modified: | 2016-02-03 | | Method: | X-RAY DIFFRACTION (2.155 Å) | | Cite: | C-terminal domain of SARS-CoV nsp8 complex with nsp7
To Be Published
|
|
8SK4
 | |
8SKH
 | | Co-structure of SARS-CoV-2 (COVID-19 with covalent pyrazoline based inhibitors | | Descriptor: | 2-chloro-1-[(4R,5R)-3,4,5-triphenyl-4,5-dihydro-1H-pyrazol-1-yl]ethan-1-one, 3C-like proteinase nsp5 | | Authors: | Knapp, M.S, Ornelas, E. | | Deposit date: | 2023-04-19 | | Release date: | 2023-06-07 | | Last modified: | 2023-06-14 | | Method: | X-RAY DIFFRACTION (1.882 Å) | | Cite: | Discovery of Potent Pyrazoline-Based Covalent SARS-CoV-2 Main Protease Inhibitors.
Chembiochem, 24, 2023
|
|
8IGZ
 | | Xcc NAMPT Quadruple mutant | | Descriptor: | Pre-B cell enhancing factor related protein | | Authors: | Xu, G.L, Ming, Z.H. | | Deposit date: | 2023-02-21 | | Release date: | 2024-02-28 | | Last modified: | 2024-05-22 | | Method: | X-RAY DIFFRACTION (3.11 Å) | | Cite: | Structural insights into Xanthomonas campestris pv. campestris NAD + biosynthesis via the NAM salvage pathway.
Commun Biol, 7, 2024
|
|
8W4Q
 | | Crystal structure of PDE4D complexed with CX-4945 | | Descriptor: | 1,2-ETHANEDIOL, 5-[(3-chlorophenyl)amino]benzo[c][2,6]naphthyridine-8-carboxylic acid, MAGNESIUM ION, ... | | Authors: | Liu, J.Y, Li, M.J, Xu, Y.C. | | Deposit date: | 2023-08-24 | | Release date: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (1.55 Å) | | Cite: | Drug repurposing and structure-based discovery of new PDE4 and PDE5 inhibitors.
Eur.J.Med.Chem., 262, 2023
|
|
8W4R
 | | Crystal structure of PDE4D complexed with CVT-313 | | Descriptor: | 1,2-ETHANEDIOL, 2,2'-{[6-{[(4-methoxyphenyl)methyl]amino}-9-(propan-2-yl)-9H-purin-2-yl]azanediyl}di(ethan-1-ol), MAGNESIUM ION, ... | | Authors: | Liu, J.Y, Li, M.J, Xu, Y.C. | | Deposit date: | 2023-08-24 | | Release date: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (1.37 Å) | | Cite: | Drug repurposing and structure-based discovery of new PDE4 and PDE5 inhibitors.
Eur.J.Med.Chem., 262, 2023
|
|
8W4S
 | | Crystal structure of PDE5A in complex with CVT-313 | | Descriptor: | 2,2'-{[6-{[(4-methoxyphenyl)methyl]amino}-9-(propan-2-yl)-9H-purin-2-yl]azanediyl}di(ethan-1-ol), MAGNESIUM ION, ZINC ION, ... | | Authors: | Liu, J.Y, Li, M.J, Xu, Y.C. | | Deposit date: | 2023-08-24 | | Release date: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (1.848 Å) | | Cite: | Drug repurposing and structure-based discovery of new PDE4 and PDE5 inhibitors.
Eur.J.Med.Chem., 262, 2023
|
|
8W4T
 | | Crystal structure of PDE5A in complex with a novel inhibitor | | Descriptor: | 2-[bis(2-hydroxyethyl)amino]-6-[(4-methoxyphenyl)methylamino]-9-propan-2-yl-7~{H}-purin-8-one, MAGNESIUM ION, ZINC ION, ... | | Authors: | Liu, J.Y, Li, M.J, Xu, Y.C. | | Deposit date: | 2023-08-24 | | Release date: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (2.199 Å) | | Cite: | Drug repurposing and structure-based discovery of new PDE4 and PDE5 inhibitors.
Eur.J.Med.Chem., 262, 2023
|
|
8WDX
 | | Crystal structure of human FABP4 complexed with C3 | | Descriptor: | 1,2-ETHANEDIOL, 2-[(3-chloranyl-2-phenyl-phenyl)amino]-6-methyl-benzoic acid, Fatty acid-binding protein, ... | | Authors: | Xie, H, Chen, G.F, Xu, Y.C. | | Deposit date: | 2023-09-16 | | Release date: | 2023-12-27 | | Method: | X-RAY DIFFRACTION (1.65 Å) | | Cite: | Structure-based design of potent FABP4 inhibitors with high selectivity against FABP3.
Eur.J.Med.Chem., 264, 2023
|
|
8WE3
 | | Crystal structure of human FABP4 complexed with C7 | | Descriptor: | 2-[(3-chloranyl-2-phenyl-phenyl)amino]-5-fluoranyl-benzoic acid, Fatty acid-binding protein, adipocyte | | Authors: | Xie, H, Chen, G.F, Xu, Y.C, Li, M.J. | | Deposit date: | 2023-09-16 | | Release date: | 2023-12-27 | | Method: | X-RAY DIFFRACTION (1.82 Å) | | Cite: | Structure-based design of potent FABP4 inhibitors with high selectivity against FABP3.
Eur.J.Med.Chem., 264, 2023
|
|
8K4H
 | | Crystal structure of PDE4D complexed with benzbromarone | | Descriptor: | 1,2-ETHANEDIOL, MAGNESIUM ION, ZINC ION, ... | | Authors: | Liu, J.Y, Li, M.J, Xu, Y.C. | | Deposit date: | 2023-07-18 | | Release date: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (1.95 Å) | | Cite: | Drug repurposing and structure-based discovery of new PDE4 and PDE5 inhibitors.
Eur.J.Med.Chem., 262, 2023
|
|
